Kooij Louise Frederika sold $2.3M of NAMS
Kooij Louise Frederika (Chief Accounting Officer) sold 65,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at $35.69 ($2.32M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
No operational or financial update is included; the disclosure mainly informs positioning and sentiment rather than fundamentals.
Market read
A planned insider sale ($2.32M) is disclosed; likely limited trading impact absent other catalysts.
What to watch
Insider sales can still influence short-term order flow if the market is already sensitive to insider activity, even when planned.
Background
The filing is an SEC Form 4 insider transaction by Kooij Louise Frederika (Chief Accounting Officer) for NewAmsterdam Pharma.
Ticker impact
NewAmsterdam Pharma’s CFO sold $2.32M of NAMS stock via an open-market transaction under a pre-arranged 10b5-1 plan.
Low probability of sustained price impact; any reaction is likely limited to short-term sentiment/positioning.
Form 4 shows a planned 10b5-1 sale by an accounting officer, with no accompanying fundamental company news.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated beyond routine US-listed insider disclosure effects.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than negative expectations.
Key entities
- issuerNewAmsterdam Pharma Co N.V.
Subject of the insider transaction disclosure; CFO-level officer sold shares under a 10b5-1 plan.
- insiderKooij Louise Frederika
Chief Accounting Officer who executed the open-market sale.
